This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schuhmacher, J. Articles by Bastert, G. Search for Related Content PubMed PubMed Citation Articles by Schuhmacher, J. Articles by Bastert, G.

Immunoscintigraphy with Positron Emission Tomography

Gallium-68 Chelate Imaging of Breast Cancer Pretargeted with Bispecific Anti-MUC1/Anti-Ga Chelate Antibodies

Departments of Diagnostic and Therapeutic Radiology [J. S., G. K., J. D.] and Cellular and Molecular Pathology [F. A.], German Cancer Research Center, D-69120 Heidelberg, Germany and Departments of Gynecological Oncology [S. K., A. M., G. B.], Gynecological and Obstetrical Radiology [H. J.], and Nuclear Medicine [M. H., U. H.], University of Heidelberg, D-69115 Heidelberg, Germany

Pretargeting techniques that are based on the sequential administrations of bispecific antitumor/antimetal chelate antibodies (BS-MAbs), a blocker to saturate the anti-chelate binding sites of the BS-MAb still present in the circulation, and the radiolabeled chelate are suitable to increase tumor-to-normal tissue contrasts and enable positron emission tomography (PET) as an imaging method. As demonstrated in the nude mouse model, a combination of pretargeted immunoscintigraphy and PET markedly improved the detection of tumor xenografts. With the presented preliminary clinical trial, we attempted to assess the efficacy of pretargeting and PET for breast cancer localization in patients. The BS-MAb used for pretargeting was synthesized from the F(ab')₂ fragments of the anti-MUC1 MAb 12H12, which reacts with the vast majority of breast tumors, and the F(ab') fragments of an anti-gallium (Ga) chelate MAb via a mixed functional chemical linker. For labeling of the Ga-chelate, we used the short-lived positron emitter Ga-68 (t_1/2, 68 min; ß⁺, 88%). The dose and time schedule of pretargeting was deduced from previous animal experiments. Ten patients with biopsy-proven, primary breast carcinoma were infused with 10 mg of the BS-MAb. Eighteen h later, they received i.v. injections of 10.7 mg of a blocker and, 15 min later, 9.6 µg of the Ga chelate labeled with 230–300 MBq of ⁶⁸Ga. PET imaging was started 60–90 min after injection of the ⁶⁸Ga chelate. Average tumor-to-blood and tumor:normal breast tissue ratios were 0.9 and 3.0 at 1 h postinjection. Tumor uptake amounted to 0.003% iD/g corresponding to a standard uptake value of 2. Blood clearance of the ⁶⁸Ga chelate showed a t_1/2 ß of 100 min. Fourteen of 17 known lesions, averaging 25 ± 16 mm in size, were clearly visualized as foci of increased activity with PET. No false-positive but three false-negative readings were obtained. An enhanced, bilateral activity uptake in the whole breast parenchyma, found in 4 of the 10 patients, compromised the recognition of these tumor sites. Although the shedding of the MUC1 antigen and the comparatively low tumor affinity of the BS-MAb, common to all anti-mucin MAbs, proved not to be optimal for increasing tumor:tissue ratios with a pretargeting technique, PET imaging offered better sensitivity for the detection of breast cancer at low tumor contrasts than conventional immunoscintigraphy. This could be demonstrated by the clear visualization of tumor sites 10 mm in size, which contrasted only by a factor of 2 from surrounding normal breast tissue.

This article has been cited by other articles:

				G. A.M.S. van Dongen, G. W.M. Visser, M. N. Lub-de Hooge, E. G. de Vries, and L. R. Perk Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications Oncologist, December 1, 2007; 12(12): 1379 - 1389. [Abstract] [Full Text] [PDF]

				D. M. Goldenberg, R. M. Sharkey, G. Paganelli, J. Barbet, and J.-F. Chatal Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy J. Clin. Oncol., February 10, 2006; 24(5): 823 - 834. [Abstract] [Full Text] [PDF]

				R. M. Sharkey, H. Karacay, T. M. Cardillo, C.-H. Chang, W. J. McBride, E. A. Rossi, I. D. Horak, and D. M. Goldenberg Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods Clin. Cancer Res., October 1, 2005; 11(19): 7109s - 7121s. [Abstract] [Full Text] [PDF]

				I. Verel, G. W.M. Visser, and G. A. van Dongen The Promise of Immuno-PET in Radioimmunotherapy J. Nucl. Med., January 1, 2005; 46(1_suppl): 164S - 171S. [Abstract] [Full Text] [PDF]

				T. M. Cardillo, H. Karacay, D. M. Goldenberg, D. Yeldell, C.-H. Chang, D. E. Modrak, R. M. Sharkey, and D. V. Gold Improved Targeting of Pancreatic Cancer: Experimental Studies of a New Bispecific Antibody, Pretargeting Enhancement System for Immunoscintigraphy Clin. Cancer Res., May 15, 2004; 10(10): 3552 - 3561. [Abstract] [Full Text] [PDF]

				G. L. Griffiths, C.-H. Chang, W. J. McBride, E. A. Rossi, A. Sheerin, G. R. Tejada, H. Karacay, R. M. Sharkey, I. D. Horak, H. J. Hansen, et al. Reagents and Methods for PET Using Bispecific Antibody Pretargeting and 68Ga-Radiolabeled Bivalent Hapten-Peptide-Chelate Conjugates J. Nucl. Med., January 1, 2004; 45(1): 30 - 39. [Abstract] [Full Text] [PDF]

				M. Jain and S. K. Batra Genetically Engineered Antibody Fragments and PET Imaging: A New Era of Radioimmunodiagnosis J. Nucl. Med., December 1, 2003; 44(12): 1970 - 1972. [Full Text] [PDF]

				O. C. Boerman, F. G. van Schaijk, W. J.G. Oyen, and F. H.M. Corstens Pretargeted Radioimmunotherapy of Cancer: Progress Step by Step J. Nucl. Med., March 1, 2003; 44(3): 400 - 411. [Abstract] [Full Text] [PDF]

				M Schwaiger Functional imaging for assessment of therapy Br. J. Radiol., November 1, 2002; 75(90009): S67 - 73. [Full Text] [PDF]

				C.-H. Chang, R. M. Sharkey, E. A. Rossi, H. Karacay, W. McBride, H. J. Hansen, J.-F. Chatal, J. Barbet, and D. M. Goldenberg Molecular Advances in Pretargeting Radioimunotherapy with Bispecific Antibodies Mol. Cancer Ther., May 1, 2002; 1(7): 553 - 563. [Abstract] [Full Text] [PDF]